Hartaj Singh
Stock Analyst at Oppenheimer
(1.71)
# 3,408
Out of 5,090 analysts
108
Total ratings
45.54%
Success rate
-8.49%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $22.26 | +66.22% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $718.36 | +25.29% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $121.22 | +3.12% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $455.48 | - | 17 | Dec 19, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $79.99 | - | 6 | Dec 11, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $12.93 | +116.55% | 6 | Nov 14, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $489.31 | +22.62% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $27.70 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $4.74 | +110.97% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.22 | +4,818.03% | 5 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $3.85 | +133.77% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $2.07 | +1,832.37% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $10.34 | +112.77% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.74 | +37,256.32% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $18.31 | +63.84% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $22.26
Upside: +66.22%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $718.36
Upside: +25.29%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $121.22
Upside: +3.12%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $455.48
Upside: -
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $79.99
Upside: -
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $12.93
Upside: +116.55%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $489.31
Upside: +22.62%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $27.70
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $4.74
Upside: +110.97%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.22
Upside: +4,818.03%
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $3.85
Upside: +133.77%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $2.07
Upside: +1,832.37%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $10.34
Upside: +112.77%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.74
Upside: +37,256.32%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $18.31
Upside: +63.84%